Adequate hydration supports kidney function, helps manage potential side effects, and can help distinguish between hunger and thirst
Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years News provided by Prime Therapeutics LLC Jun 25, 2025, 10:00 ET Findings also show improved persistence with high-potency, obesity-approved GLP-1 products EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from pharmacy solutions partner Prime Therapeutics LLC (Prime)
Disclaimer: This post is for educational purposes only and does not substitute for professional medical advice, diagnosis, or treatment
Emotion: Acknowledge the emotional impact of hair loss but focus on your health goals and give yourself time to adjust
If youre ready to experience the benefits of glutathione IV therapy for yourself, The Daily Aesthetics is here to help